Claims cover method of treating a viral infection with a lectin-binding carbohydrate
Google Patent link:
https://patents.google.com/patent/WO2023178228A1/en
The glycovirology platform is a market forming technology with potentially wide-reaching implications. This patent represents what we believe is a new direction in the evolution of antiviral therapies that originally started during the HIV epidemic. The first antiviral agents were nucleoside/nucleotide reverse transcriptase inhibitors (NRTI’s) which would make their way to the infected cells and prevent the cell from reading the viral code and converting it into copying DNA. As drug resistance emerged, protease inhibitors which cleave the polypeptides into usable viral proteins were blocked to disrupt the viral replication process. Eventually a combination of therapies known as Highly Active Antiretroviral therapy (HAART) became the standard of care for the past 25 years. The current Mechanism of Action (MOA) of almost all antivirals traces its roots to the disruption of the viral replication cycle.
This is possibly a groundbreaking patent because we believe it is the first of its kind in the field of glycovirology. The broad claims in terms of combinations of molecules and the number of viruses likely affected a present and pre-eminent position in this field of research. Being the first in the field and progressing closer to a registrational trial demonstrates the Company is a leader in drug development in this field. This pending patent with its broad claims also shows the Company is well-positioned with respect to its intellectual property portfolio. We believe according to this patent, if issued any future drug developers looking to enter the field of glycovirology will need to license the necessary technology. This field of research holds so much promise there exists the potential for there to be a rush to develop drugs which could rival that of the movement to develop antibiotics which occurred after the first use of penicillin.
“This patent represents a huge expansion of our intellectual property in the field of glycovirology,” said Dr.
About ProLectin-M
ProLectin-M is an oral galectin antagonist that prevents the entry of the SARS-CoV-2 virus into human cells. In recent clinical trials the drug achieved a 100% responders rate of negative PCR tests by day 7. In 3 days, the drug achieved an 88% responders rate of negative PCR tests. The treated population experienced no viral rebounds during the 14-day observation period. The company is preparing for a phase 3 clinical trial in order to seek regulatory approval.
About
Investor Relations
509-991-0245
mike.sheikh@bioxytraninc.com
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended
Source:
2023 GlobeNewswire, Inc., source